HEPA Archives | BioTuesdays

Developments

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

Hepion Pharmaceuticals (NASDAQ:HEPA) is initiating a Phase 2b clinical trial after releasing additional positive efficacy data from its Phase 2a AMBITION trial with CRV431 for the treatment of non-alcoholic...

September 13, 2021

Developments

Hepion posts positive Phase 2a NASH data in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that all primary endpoints were met in its Phase 2a AMBITION clinical trial in patients with non-alcoholic steatohepatitis (NASH). The Phase 2a trial was designed to...

July 13, 2021

Developments

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Hepion Pharmaceuticals (NASDAQ:HEPA) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. Membership in the...

June 9, 2021

Developments

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) completed recruitment for its Phase 2a AMBITION clinical trial, with all non-alcoholic steatohepatitis (NASH) patients in the 225 mg CRV431 dosing cohort now enrolled. After...

May 6, 2021

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) and ENDRA Life Sciences (NASDAQ:NDRA) signed a collaboration agreement to incorporate ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS) as an add-on technology to support...

March 18, 2021

Markets

Hepion Pharma closes $88.4-million offering

Hepion Pharmaceuticals (NASDAQ:HEPA) closed a public offering of 44.2 million common shares at a price of $2 each for gross proceeds of $88.4-million. After deducting underwriting fees and other offering expenses, net...

February 18, 2021

Executive Moves

Hepion names renowned clinician Dr. Todd Hobbs as CMO

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Todd Hobbs, M.D., to the newly created position of chief medical officer, effective Feb. 16, 2021. In this role, Dr. Hobbs will help lead Hepion as it engages with the FDA...

February 10, 2021

Developments

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...

December 30, 2020

Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...

December 29, 2020

Tag - HEPA

Hepion Pharma moving into Phase 2b NASH trial after additional positive Phase 2a data

Hepion posts positive Phase 2a NASH data in AMBITION trial

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharma closes $88.4-million offering

Hepion names renowned clinician Dr. Todd Hobbs as CMO

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

General

More